Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2024-11-07 Regulatory Filings
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2024-11-07 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel at Sanofi India Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including management changes. The content details the resignation of one senior manager and the appointment of another, including dates and brief profiles. There is no financial data, earnings information, or report publication mentioned. The document fits the definition of Board/Management Information (MANG) as it announces changes in the company's senior management.
2024-11-06 English
Change in Senior Management Personnel of the Company.
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel at Sanofi India Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including management changes. The content details the resignation of one senior manager and the appointment of another, including dates and brief profiles. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of management changes, fitting the category of Board/Management Information (MANG). The document length is 4383 characters, which is consistent with a detailed announcement rather than a full report or transcript.
2024-11-06 English
Board Meeting — SANOFI INDIA LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the…
Regulatory Filings
2024-10-17 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification about a forthcoming Board of Directors meeting scheduled for November 7, 2024, to approve unaudited financial statements for the quarter and nine months ended September 30, 2024. It also mentions the closure of the trading window related to the publication of these financial statements. The document is short (2004 characters) and serves as an announcement rather than containing any financial data or the actual financial report. It is a regulatory announcement informing stock exchanges and stakeholders about the board meeting and trading window closure. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication, not as the financial report itself or a detailed management report.
2024-10-17 English
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 ,inter alia, to consider and approve the Unaudited Financial Statements ....
Regulatory Filings Classification · 95% confidence The document is a formal notification from the company Sanofi India Limited to stock exchanges about an upcoming Board of Directors meeting scheduled for November 7, 2024. The purpose of the meeting includes approval of unaudited financial statements for the quarter and nine months ended September 30, 2024. The document also mentions the closure of the trading window in relation to the publication of these financial statements. The document is short (2004 characters) and serves as an announcement of a future event (board meeting) rather than the financial report itself. It does not contain any financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Earnings Release.
2024-10-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.